RT期刊文章SR电子T1手术或I期肺癌的放疗？意向性治疗分析JF欧洲呼吸杂志JO EUR呼吸J FD欧洲呼吸学会SP 1801568 DO 10.1183/13993003.01568-2018 VO 53 I188bet官网地址S 6 A1 Spencer，Katie L. A1 Kennedy，Martyn P.T.A1 Lummis，Katie L. A1 Ellames，Deborah A.B.A1 Snee，Michael A1 Brunelli，Alessandro A1 Franks，Kevin A1 Callister，Matthew E.J.YR 2019 UL //www.qdcxjkg.com/content/53/6/6/1801568.Abstract AB ABS Trucd介绍手术是早期肺癌的护理标准，具有立体定向的体液放射疗法（SABR），是较低的发病率。生理储备有限的患者。这些治疗方案之间结果的比较受到竞争合并症和治疗前病理信息差异的限制。这项研究的目的是通过在意图处理的基础上评估假定的I期肺癌的整体和癌症特异性生存，以解决这些问题。在一个大型英国中心。通过调整使用COX比例危害和罚款竞争风险分析的混杂变量来评估整体生存，癌症特异性生存以及与治疗相关的癌症和治疗相关的生存。 study population. Compared with surgery, SABR was associated with inferior overall survival on multivariable Cox modelling (SABR HR 1.84 (95% CI 1.32–2.57)), but there was no difference in cancer-specific survival (SABR HR 1.47 (95% CI 0.80–2.69)) or combined cancer and treatment-related survival (SABR HR 1.27 (95% CI 0.74–2.17)). Combined cancer and treatment-related death was no different between SABR and surgery on Fine–Gray competing risks multivariable modelling (subdistribution hazard 1.03 (95% CI 0.59–1.81)). Non-cancer-related death was significantly higher in SABR than surgery (subdistribution hazard 2.16 (95% CI 1.41–3.32)).Conclusion In this analysis, no difference in cancer-specific survival was observed between SABR and surgery. Further work is needed to define predictors of outcome and help inform treatment decisions.No difference seen in cancer- and treatment-specific survival following surgery and SABR. Inferior overall survival may reflect unobserved confounding. Further prospective work should assess quality of life outcomes to support shared decision making. http://ow.ly/7s5t30njP0B